Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis
Mohamed A. Kharfan‐Dabaja, Tea Reljic, Hemant S. Murthy, et al.
Clinical Lymphoma Myeloma & Leukemia (2018) Vol. 18, Iss. 11, pp. 703-709.e1
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S. Kanate, Navneet S. Majhail, Bipin N. Savani, et al.
Biology of Blood and Marrow Transplantation (2020) Vol. 26, Iss. 7, pp. 1247-1256
Open Access | Times Cited: 214
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4238-4251
Open Access | Times Cited: 104
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek Upadhyay, et al.
Blood (2019) Vol. 134, Iss. 8, pp. 678-687
Open Access | Times Cited: 84
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Plasmacytoid dendritic cell neoplasms
Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, et al.
Blood Research (2023) Vol. 58, Iss. S1, pp. S90-S95
Open Access | Times Cited: 19
Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights
Sangeetha Venugopal, Selena Zhou, Siraj M. El Jamal, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 9, pp. 545-554
Closed Access | Times Cited: 47
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Qaiser Bashir, Denái R. Milton, Uday Popat, et al.
Bone Marrow Transplantation (2021) Vol. 57, Iss. 1, pp. 51-56
Open Access | Times Cited: 32
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Hemant S. Murthy, Mei‐Jie Zhang, Karen Chen, et al.
Blood Advances (2023) Vol. 7, Iss. 22, pp. 7007-7016
Open Access | Times Cited: 12
A case series of oral decitabine–cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm
Hannah Goulart, Guillermo Garcia‐Manero, Tapan M. Kadia, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-4
Closed Access
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm
Danielle Hammond, Naveen Pemmaraju
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 565-574
Closed Access | Times Cited: 24
Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations
Evgenii Shumilov, Paolo Mazzeo, Susanne Ghandili, et al.
Annals of Hematology (2024) Vol. 103, Iss. 5, pp. 1587-1599
Open Access | Times Cited: 3
Blastic Plasmacytoid Dendritic Cell Neoplasm
Éric Deconinck, Tony Petrella, Francine Garnache Ottou
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 491-500
Open Access | Times Cited: 21
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Marlise R. Luskin, Andrew A. Lane
Haematologica (2023)
Open Access | Times Cited: 8
Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches
Wei Cheng, Tiantian Yu, Aiping Tang, et al.
Current Medical Science (2021) Vol. 41, Iss. 3, pp. 405-419
Open Access | Times Cited: 18
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
Margaux Poussard, Fanny Angelot‐Delettre, Éric Deconinck
Cancers (2022) Vol. 14, Iss. 15, pp. 3767-3767
Open Access | Times Cited: 12
Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature
Chan Liao, Nan-Xia Hu, Hua Song, et al.
International Journal of Hematology (2021) Vol. 113, Iss. 5, pp. 751-759
Closed Access | Times Cited: 16
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
Michael Haddadin, Justin Taylor
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 539-552
Closed Access | Times Cited: 15
<p>Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data</p>
Guillaume Béziat, Loïc Ysebaert
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 5199-5205
Open Access | Times Cited: 15
Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey
Caterina Giovanna Valentini, Alfonso Piciocchi, Fabio Facchetti, et al.
Blood Advances (2021) Vol. 5, Iss. 24, pp. 5608-5611
Open Access | Times Cited: 13
Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm
Mohamed A. Kharfan‐Dabaja, Mohamad Cherry
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 621-629
Closed Access | Times Cited: 14
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database
Xiao-Jing Lin, Li Wang, Qian Hu, et al.
European Journal Of Haematology (2023) Vol. 110, Iss. 6, pp. 743-753
Closed Access | Times Cited: 5
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation
Song‐Yau Wang, Katrin Thomassen, Lars Kurch, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 7, pp. e579-e582
Closed Access | Times Cited: 11
Dendritic Cell Leukemia: a Review
Nikolaos J. Tsagarakis, Georgios Paterakis
Current Oncology Reports (2020) Vol. 22, Iss. 6
Closed Access | Times Cited: 11
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Yumeng Zhang, Lubomir Sokol
Cancer Management and Research (2022) Vol. Volume 14, pp. 2107-2117
Open Access | Times Cited: 7
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
Peter‐Martin Bruch, Sascha Dietrich, Hervé Finel, et al.
Leukemia (2022) Vol. 37, Iss. 2, pp. 465-472
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top